ES2277460T3
(es)
|
1998-12-14 |
2007-07-01 |
Genetics Institute, Llc |
Cadena del receptor de la citoquina.
|
US7553487B2
(en)
|
1998-12-14 |
2009-06-30 |
Genetics Institute, Llc |
Method and compositions for treating asthma
|
WO2003025019A1
(en)
*
|
2001-09-20 |
2003-03-27 |
Alexion Pharmaceuticals, Inc. |
Anti-pdgf antibodies and methods for producing engineered antibodies
|
EP2272566A3
(en)
*
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisation of antibodies
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
TWI333977B
(en)
|
2003-09-18 |
2010-12-01 |
Symphogen As |
Method for linking sequences of interest
|
EP1761561B1
(en)
*
|
2004-01-20 |
2015-08-26 |
KaloBios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
US20090098142A1
(en)
*
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
PT3540062T
(pt)
*
|
2004-11-16 |
2021-07-06 |
Humanigen Inc |
Permuta de cassete de região variável de imunoglobulina
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
JP5732182B2
(ja)
|
2006-10-27 |
2015-06-10 |
エルパス・インコーポレイテッドLpath, Inc. |
眼疾患と症状を処置するための組成物および方法
|
ES2524059T3
(es)
|
2006-10-27 |
2014-12-03 |
Lpath, Inc. |
Composiciones y procedimientos de unión a esfingosina-1-fosfato
|
ES2369946T3
(es)
|
2007-03-01 |
2011-12-09 |
Symphogen A/S |
Procedimiento para clonación de anticuerpos análogos.
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
CA2685123A1
(en)
*
|
2007-04-23 |
2008-10-30 |
Wyeth |
Methods and compositions for treating and monitoring treatment of il-13-associated disorders
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US8158124B2
(en)
|
2007-05-30 |
2012-04-17 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
AR068563A1
(es)
|
2007-09-26 |
2009-11-18 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo mutante
|
US20090087443A1
(en)
|
2007-09-27 |
2009-04-02 |
Bartels Stephen P |
Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
WO2009062050A2
(en)
|
2007-11-08 |
2009-05-14 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
CN108610416B
(zh)
|
2008-10-13 |
2022-01-14 |
生物医学研究所 |
登革热病毒中和抗体及其用途
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
AR074369A1
(es)
*
|
2008-11-20 |
2011-01-12 |
Genentech Inc |
Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
CN102573905A
(zh)
*
|
2008-12-05 |
2012-07-11 |
勒帕斯公司 |
利用抗脂类抗体晶体结构的抗体设计
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
EP2385955B1
(en)
|
2009-01-12 |
2020-08-12 |
CytomX Therapeutics, Inc. |
Modified antibody compositions, methods of making and using thereof
|
WO2010096838A2
(en)
*
|
2009-02-23 |
2010-08-26 |
Cytomx Therapeutics, Llc |
Proproteins and methods of use thereof
|
WO2010098863A1
(en)
*
|
2009-02-26 |
2010-09-02 |
Lpath, Inc. |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
CA2753988C
(en)
|
2009-03-25 |
2017-04-25 |
Genentech, Inc. |
Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010121093A2
(en)
*
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
WO2011006001A1
(en)
|
2009-07-09 |
2011-01-13 |
Genentech, Inc. |
Animal model for the evaluation of adjuvant therapies of cancer
|
AU2010273585B2
(en)
|
2009-07-13 |
2015-04-23 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
EP3431588A1
(en)
|
2009-08-11 |
2019-01-23 |
F. Hoffmann-La Roche AG |
Production of proteins in glutamine-free cell culture media
|
CN102575298A
(zh)
|
2009-08-14 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
用于监测患者对vegf拮抗剂的响应的生物学标志物
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
JP2013504595A
(ja)
|
2009-09-11 |
2013-02-07 |
ジェネンテック, インコーポレイテッド |
抗癌剤に対する応答の可能性が増加した患者を同定するための方法
|
CA2772670A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
AU2010300747A1
(en)
|
2009-09-30 |
2012-04-26 |
Genentech, Inc. |
Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
AR078377A1
(es)
|
2009-12-11 |
2011-11-02 |
Genentech Inc |
Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
|
MY159156A
(en)
|
2009-12-21 |
2016-12-15 |
Genentech Inc |
Antibody formulation
|
EP2516465B1
(en)
|
2009-12-23 |
2016-05-18 |
F.Hoffmann-La Roche Ag |
Anti-bv8 antibodies and uses thereof
|
US20110212106A1
(en)
|
2010-01-20 |
2011-09-01 |
Institute For Research In Bioscience |
Hiv-1 neutralizing antibodies and uses thereof
|
SI2536748T1
(sl)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
|
WO2011106723A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Lpath, Inc. |
Anti-paf antibodies
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
KR20150013949A
(ko)
|
2010-07-19 |
2015-02-05 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
EP2596362A1
(en)
|
2010-07-19 |
2013-05-29 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
TW201209063A
(en)
|
2010-08-13 |
2012-03-01 |
Roche Glycart Ag |
Anti-tenascin-C A2 antibodies and methods of use
|
BR112013003361B8
(pt)
|
2010-08-13 |
2022-01-25 |
Roche Glycart Ag |
Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
SG187965A1
(en)
|
2010-08-27 |
2013-04-30 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
CA2810016A1
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
SG190682A1
(en)
|
2010-11-10 |
2013-07-31 |
Genentech Inc |
Methods and compositions for neural disease immunotherapy
|
RU2016123839A
(ru)
|
2010-12-08 |
2018-11-30 |
АббВай Стемсентркс ЭлЭлСи |
Новые модуляторы и способы их применения
|
US20120156194A1
(en)
|
2010-12-16 |
2012-06-21 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
WO2012093068A1
(en)
|
2011-01-03 |
2012-07-12 |
F. Hoffmann-La Roche Ag |
A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
JP2014511147A
(ja)
|
2011-02-10 |
2014-05-12 |
ロシュ グリクアート アーゲー |
改善された免疫療法
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012125569A2
(en)
|
2011-03-11 |
2012-09-20 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
BR112013024717A2
(pt)
|
2011-04-07 |
2017-08-08 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
MY175338A
(en)
|
2011-05-16 |
2020-06-19 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
US8846042B2
(en)
|
2011-05-16 |
2014-09-30 |
Fabion Pharmaceuticals, Inc. |
Multi-specific FAB fusion proteins and methods of use
|
AR086924A1
(es)
|
2011-06-15 |
2014-01-29 |
Hoffmann La Roche |
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
|
CA2835242A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CN103842030B
(zh)
|
2011-08-01 |
2018-07-31 |
霍夫曼-拉罗奇有限公司 |
使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
MX2014001736A
(es)
|
2011-08-17 |
2014-03-31 |
Genentech Inc |
Inhibicion de angiogenesis en tumores refractarios.
|
MX356947B
(es)
|
2011-08-23 |
2018-06-20 |
Roche Glycart Ag |
Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
US9309306B2
(en)
|
2011-08-23 |
2016-04-12 |
Roche Glycart Ag |
Anti-MCSP antibodies
|
LT2748201T
(lt)
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
US20130060011A1
(en)
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Fc-free antibodies comprising two fab fragments and methods of use
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
SG11201401287SA
(en)
|
2011-10-05 |
2014-05-29 |
Genentech Inc |
Methods of treating liver conditions using notch2 antagonists
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
TW201325613A
(zh)
|
2011-10-28 |
2013-07-01 |
Genentech Inc |
治療黑色素瘤之治療組合及方法
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
JP6138813B2
(ja)
|
2011-11-28 |
2017-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗pd−l1抗体及びその使用
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
EP2794651B1
(en)
|
2011-12-22 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
US9963511B2
(en)
|
2011-12-22 |
2018-05-08 |
Hoffmann-La Roche Inc. |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
SG11201403445YA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Full length antibody display system for eukaryotic cells and its use
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
CA2858806A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
KR20140114415A
(ko)
|
2012-01-13 |
2014-09-26 |
제넨테크, 인크. |
Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
|
SG10201601747XA
(en)
|
2012-01-18 |
2016-04-28 |
Genentech Inc |
Anti-LRP5 Antibodies And Methods Of Use
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
JP6545959B2
(ja)
|
2012-02-11 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
Rスポンジン転位およびその使用方法
|
ES2676031T3
(es)
|
2012-02-15 |
2018-07-16 |
F. Hoffmann-La Roche Ag |
Cromatografía de afinidad basada en el receptor Fc
|
JP6401060B2
(ja)
|
2012-02-24 |
2018-10-03 |
アッヴィ・ステムセントルクス・エル・エル・シー |
抗sez6抗体及び使用方法
|
PE20190658A1
(es)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
Moduladores y metodos de empleo novedosos
|
DK2825558T3
(da)
|
2012-03-13 |
2019-07-22 |
Hoffmann La Roche |
Kombinationsterapi til behandling af ovariecancer
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013148288A1
(en)
|
2012-03-30 |
2013-10-03 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
US10114023B2
(en)
|
2012-04-18 |
2018-10-30 |
Massachusetts Institute Of Technology |
Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV
|
CN104470544B
(zh)
|
2012-05-01 |
2018-01-12 |
基因泰克公司 |
抗pmel17抗体和免疫缀合物
|
US9480449B2
(en)
|
2012-05-03 |
2016-11-01 |
Fibrogen, Inc. |
Methods for treating idiopathic pulmonary fibrosis
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
TW201410706A
(zh)
|
2012-06-15 |
2014-03-16 |
Genentech Inc |
抗-pcsk9抗體、調配物、劑量及使用方法
|
HUE029435T2
(en)
|
2012-07-04 |
2017-02-28 |
Hoffmann La Roche |
Anti-theophylline antibodies and methods of their application
|
WO2014006124A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Covalently linked antigen-antibody conjugates
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
CA3188124A1
(en)
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
SG11201500087VA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
CA2874904A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
AR091700A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b
|
EP2869847B1
(en)
|
2012-07-09 |
2017-12-06 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
WO2014009465A1
(en)
|
2012-07-13 |
2014-01-16 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
MX365382B
(es)
|
2012-08-07 |
2019-05-31 |
Roche Glycart Ag |
Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
|
WO2014025813A1
(en)
|
2012-08-07 |
2014-02-13 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
MA20150232A1
(fr)
|
2012-08-08 |
2015-07-31 |
Roche Glycart Ag |
Protéines de fusion de l'interleukine-10 et leurs utilisations
|
CN109705218B
(zh)
|
2012-08-09 |
2022-07-19 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
WO2014033252A1
(en)
*
|
2012-08-31 |
2014-03-06 |
arGEN-X BV |
Method for producing antibody molecules having inter-species, intra-target cross-reactivity
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
SG11201502538TA
(en)
|
2012-11-08 |
2015-05-28 |
Hoffmann La Roche |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
EP2916872B1
(en)
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
CA2890669A1
(en)
|
2012-11-13 |
2014-05-22 |
Genetech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
JP6462591B2
(ja)
|
2013-02-22 |
2019-01-30 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規抗体コンジュゲートおよびその使用
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
DK2961771T3
(da)
|
2013-02-26 |
2020-03-02 |
Roche Glycart Ag |
Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
LT2968466T
(lt)
|
2013-03-13 |
2018-10-10 |
F. Hoffmann-La Roche Ag |
Sumažintos oksidacijos kompozicijos
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
AR095396A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones de anticuerpo
|
BR112015022019A2
(pt)
|
2013-03-14 |
2017-08-29 |
Genentech Inc |
Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
CN110420333A
(zh)
|
2013-03-14 |
2019-11-08 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US9649375B2
(en)
|
2013-03-14 |
2017-05-16 |
The Administrators Of The Tulane Educational Fund |
Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
|
SG10201706210WA
(en)
|
2013-03-15 |
2017-09-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
MY176706A
(en)
|
2013-03-15 |
2020-08-19 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
CN105143258B
(zh)
|
2013-03-15 |
2020-06-23 |
Ac免疫有限公司 |
抗Tau抗体和使用方法
|
WO2014144865A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
EP2978440B1
(en)
|
2013-03-27 |
2019-10-02 |
Cedars-Sinai Medical Center |
Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
EP2983710B1
(en)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
EP2992010B1
(en)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
JP2016528168A
(ja)
|
2013-04-29 |
2016-09-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
FcRn結合が無効となった抗IGF−1R抗体及び血管性眼疾患の処置におけるそれらの使用
|
CA2908743A1
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
US10071169B2
(en)
|
2013-06-20 |
2018-09-11 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
CN105517577A
(zh)
|
2013-06-21 |
2016-04-20 |
先天制药公司 |
多肽的酶促偶联
|
WO2015006507A1
(en)
|
2013-07-09 |
2015-01-15 |
Annexon, Inc. |
Methods of treatment for alzheimer's disease and huntington's disease
|
RS60826B1
(sr)
|
2013-07-16 |
2020-10-30 |
Hoffmann La Roche |
Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
WO2015010108A1
(en)
|
2013-07-19 |
2015-01-22 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
NZ715201A
(en)
|
2013-08-01 |
2021-12-24 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス, インコーポレイテッド |
新規sez6モジュレーターおよび使用方法
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
SG11201601770YA
(en)
*
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
SI3049441T1
(sl)
|
2013-09-27 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Formulacije protiteles proti PD-L1
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
JP6715767B2
(ja)
|
2013-10-23 |
2020-07-01 |
ジェネンテック, インコーポレイテッド |
好酸球性疾患の診断及び治療方法
|
KR20160070191A
(ko)
|
2013-11-06 |
2016-06-17 |
스템센트알엑스 인코포레이티드 |
신규한 항-클라우딘 항체 및 사용 방법
|
AU2014345712B2
(en)
*
|
2013-11-07 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti CD20 antibody with a BTK inhibitor
|
SI3071597T1
(sl)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti alfa-sinukleinska protitelesa in postopki uporabe
|
JP6549143B2
(ja)
|
2013-12-09 |
2019-07-24 |
アラコス インコーポレイテッド |
抗シグレック−8抗体およびその使用の方法
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
CA2933881A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
MX2016007208A
(es)
|
2013-12-20 |
2016-07-21 |
Hoffmann La Roche |
Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ.ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
BR112016013849A2
(pt)
|
2014-01-03 |
2017-10-10 |
Hoffmann La Roche |
conjugados de anticorpos biespecíficos antihapteno/antirreceptores da barreira hematoencefálica, seus usos, e formulação farmacêutica
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
MX2016008539A
(es)
|
2014-01-15 |
2016-09-26 |
Hoffmann La Roche |
Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas.
|
JP2017505305A
(ja)
|
2014-01-24 |
2017-02-16 |
ジェネンテック, インコーポレイテッド |
抗steap1抗体及びイムノコンジュゲートを使用する方法
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
LT3102595T
(lt)
|
2014-02-06 |
2019-01-25 |
F. Hoffmann-La Roche Ag |
Interleukino-2 sulieti baltymai ir jų panaudojimas
|
PL3102230T3
(pl)
|
2014-02-08 |
2021-11-15 |
F.Hoffmann-La Roche Ag |
Sposoby leczenia choroby Alzheimera
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
MX2016010433A
(es)
|
2014-02-12 |
2016-09-22 |
Genentech Inc |
Anticuerpos anti-jagged1 y metodos de uso.
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
US10308721B2
(en)
|
2014-02-21 |
2019-06-04 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−8関連疾患を処置するための方法および組成物
|
US10435694B2
(en)
|
2014-03-14 |
2019-10-08 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
EP3126389A1
(en)
|
2014-04-02 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Method for detecting multispecific antibody light chain mispairing
|
BR112016024319B1
(pt)
|
2014-04-18 |
2024-01-23 |
Acceleron Pharma Inc |
USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
BR112016027222A2
(pt)
|
2014-05-22 |
2018-01-30 |
Genentech Inc |
anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
KR20170010785A
(ko)
|
2014-06-11 |
2017-02-01 |
제넨테크, 인크. |
항-lgr5 항체 및 이의 용도
|
BR122023023170A2
(pt)
|
2014-06-13 |
2024-02-20 |
Acceleron Pharma Inc. |
Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
AU2015277379B2
(en)
*
|
2014-06-17 |
2017-06-29 |
Academia Sinica |
Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
US10308944B2
(en)
|
2014-07-03 |
2019-06-04 |
Genentech, Inc. |
Polypeptide expression systems
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
CN106460067A
(zh)
|
2014-07-14 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
诊断方法和用于治疗成胶质细胞瘤的组合物
|
MX2017000546A
(es)
|
2014-07-15 |
2017-03-08 |
Genentech Inc |
Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
|
MA50584A
(fr)
|
2014-08-04 |
2020-09-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
|
CA3090240A1
(en)
|
2014-08-08 |
2016-02-11 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
CA2959141A1
(en)
|
2014-08-28 |
2016-03-03 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
CA2958479A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
CN106794247B
(zh)
|
2014-09-15 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
抗体配制剂
|
WO2016042684A1
(ja)
*
|
2014-09-16 |
2016-03-24 |
国立大学法人東京海洋大学 |
濃縮された生着能をもつ未分化生殖細胞を用いた生殖細胞系列への分化誘導方法
|
BR112017004953A2
(pt)
|
2014-09-17 |
2017-12-05 |
Genentech Inc |
imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
EP3223865A4
(en)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
EP3215527A4
(en)
|
2014-11-05 |
2018-04-18 |
Annexon, Inc. |
Humanized anti-complement factor c1q antibodies and uses thereof
|
JP6875276B2
(ja)
|
2014-11-05 |
2021-05-19 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
RU2020141422A
(ru)
|
2014-11-05 |
2021-01-13 |
Дженентек, Инк. |
Способы получения двуцепочечных белков в бактериях
|
PL3215528T3
(pl)
|
2014-11-06 |
2020-01-31 |
F.Hoffmann-La Roche Ag |
Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
|
CN107074966A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
MX2017006250A
(es)
|
2014-11-14 |
2017-11-17 |
Hoffmann La Roche |
Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf.
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
CA2966566C
(en)
|
2014-11-20 |
2024-03-19 |
F. Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
US10517898B2
(en)
|
2014-11-20 |
2019-12-31 |
The Regents Of The University Of California |
Compositions and methods related to hematologic recovery
|
RU2747011C2
(ru)
|
2014-11-20 |
2021-04-23 |
Ф.Хоффманн-Ля Рош Аг |
Общие легкие цепи и способы их применения
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
HUE045216T2
(hu)
|
2014-12-05 |
2019-12-30 |
Hoffmann La Roche |
Anti-CD79B antitestek és alkalmazási eljárások
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
WO2016096788A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
|
NZ733854A
(en)
|
2015-02-26 |
2022-07-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
PE20171790A1
(es)
|
2015-03-23 |
2017-12-28 |
Bayer Pharma AG |
Anticuerpos anti-ceacam6 y sus usos
|
PT3273992T
(pt)
|
2015-03-23 |
2020-08-21 |
Jounce Therapeutics Inc |
Anticorpos para icos
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
MA53400A
(fr)
|
2015-04-06 |
2021-08-04 |
Acceleron Pharma Inc |
Hétéromultimères alk7: actriib et leurs utilisations
|
EP3280441B1
(en)
|
2015-04-07 |
2021-09-29 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
AU2016267059B2
(en)
|
2015-05-22 |
2020-08-13 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
PE20180317A1
(es)
|
2015-06-05 |
2018-02-09 |
Genentech Inc |
Anticuerpos anti-tau y metodos de uso
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
TW201709934A
(zh)
|
2015-06-15 |
2017-03-16 |
建南德克公司 |
抗體及免疫結合物
|
IL256079B2
(en)
|
2015-06-16 |
2024-01-01 |
Genentech Inc |
Human antibodies with improved affinity to FCRH5 - and methods of use
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
WO2016205277A1
(en)
|
2015-06-16 |
2016-12-22 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
KR20180012859A
(ko)
|
2015-06-17 |
2018-02-06 |
제넨테크, 인크. |
항-her2 항체 및 이용 방법
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CN107921145A
(zh)
|
2015-06-23 |
2018-04-17 |
拜耳医药股份有限公司 |
Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物(adc)
|
EP3744732A1
(en)
|
2015-06-24 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Humanized anti-tau(ps422) antibodies and methods of use
|
RU2020124105A
(ru)
|
2015-06-24 |
2020-09-18 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
|
EP3514174B1
(en)
|
2015-06-29 |
2021-03-31 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
US9884900B2
(en)
|
2015-08-04 |
2018-02-06 |
Acceleron Pharma Inc. |
Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
TR201909273T4
(tr)
|
2015-08-20 |
2019-07-22 |
Hoffmann La Roche |
Bir pegile analit spesifik bağlanma ajanının kullanıldığı partikül bazlı immünolojik test.
|
CN115960235A
(zh)
|
2015-08-28 |
2023-04-14 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
BR112018002432A2
(pt)
|
2015-09-18 |
2018-09-18 |
Chugai Pharmaceutical Co Ltd |
anticorpos de ligação à il-8 e usos dos mesmos
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
KR20180083313A
(ko)
|
2015-09-24 |
2018-07-20 |
에이비비트로, 엘엘씨 |
Hiv 항체 조성물 및 사용 방법
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
JP2018529719A
(ja)
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
|
CR20180149A
(es)
|
2015-10-02 |
2018-04-05 |
Hoffmann La Roche |
Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
PE20181092A1
(es)
|
2015-10-02 |
2018-07-09 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
CN117069841A
(zh)
|
2015-10-06 |
2023-11-17 |
艾利妥 |
抗trem2抗体及其使用方法
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10968277B2
(en)
|
2015-10-22 |
2021-04-06 |
Jounce Therapeutics, Inc. |
Gene signatures for determining ICOS expression
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
SG11201803567XA
(en)
|
2015-10-29 |
2018-05-30 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
KR102162324B1
(ko)
|
2015-10-30 |
2020-10-07 |
제넨테크, 인크. |
항-HtrA1 항체 및 이의 사용 방법
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
SG10201913538VA
(en)
|
2015-11-23 |
2020-02-27 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
SG10201709415WA
(en)
|
2015-12-18 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
KR20180093078A
(ko)
|
2015-12-30 |
2018-08-20 |
제넨테크, 인크. |
단백질 제제를 위한 트립토판 유도체의 용도
|
KR20180098625A
(ko)
|
2015-12-30 |
2018-09-04 |
제넨테크, 인크. |
분해가 감소된 폴리소르베이트를 갖는 제형
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
CN107531795B
(zh)
|
2016-01-05 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
US20190016791A1
(en)
|
2016-01-20 |
2019-01-17 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3423493A2
(en)
|
2016-03-04 |
2019-01-09 |
Alector LLC |
Anti-trem1 antibodies and methods of use thereof
|
US10443054B2
(en)
|
2016-03-06 |
2019-10-15 |
Massachusetts Institute Of Technology |
Methods for identifying and treating invasive/metastatic breast cancers
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
|
US11186872B2
(en)
|
2016-03-17 |
2021-11-30 |
Cedars-Sinai Medical Center |
Methods of diagnosing inflammatory bowel disease through RNASET2
|
CR20180453A
(es)
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
JP6943872B2
(ja)
|
2016-03-25 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
多重全抗体及び抗体複合体化薬物定量化アッセイ
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Hdac抑制劑與pd-l1抑制劑之組合治療
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
TW202208441A
(zh)
|
2016-05-13 |
2022-03-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
RU2018145184A
(ru)
|
2016-05-26 |
2020-06-26 |
Мерк Патент Гмбх |
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
AU2017276604B2
(en)
|
2016-06-06 |
2020-02-27 |
F. Hoffmann-La Roche Ag |
Fusion proteins for ophthalmology with increased eye retention
|
JP7043425B2
(ja)
|
2016-06-06 |
2022-03-29 |
ジェネンテック, インコーポレイテッド |
シルベストロール抗体-薬物コンジュゲート及び使用方法
|
US20190177438A1
(en)
|
2016-06-17 |
2019-06-13 |
Life Technologies Corporation |
Site-Specific Crosslinking of Antibodies
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
AU2017289987B2
(en)
*
|
2016-06-26 |
2022-06-23 |
Gennova Biopharmaceuticals Limited, |
Antibody phage display library
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
PL3496739T3
(pl)
|
2016-07-15 |
2021-10-11 |
Acceleron Pharma Inc. |
Kompozycje zawierające polipeptydy actriia do stosowania w leczeniu nadciśnienia płucnego
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
MX2019001043A
(es)
|
2016-07-27 |
2019-09-26 |
Acceleron Pharma Inc |
Metodos y composiciones para el tratamiento de la mielofibrosis.
|
AU2017301887A1
(en)
|
2016-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-CD19 antibodies
|
WO2018026969A2
(en)
|
2016-08-03 |
2018-02-08 |
Achaogen, Inc. |
Plazomicin antibodies and methods of use
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
WO2018031865A1
(en)
|
2016-08-12 |
2018-02-15 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
FI3528838T3
(fi)
|
2016-09-23 |
2023-10-02 |
Hoffmann La Roche |
IL-13-antagonistien käyttöjä atooppisen ihottuman hoitamiseksi
|
WO2018064299A1
(en)
|
2016-09-29 |
2018-04-05 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
EP3522934A4
(en)
|
2016-10-05 |
2020-04-15 |
Acceleron Pharma Inc. |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF RENOPATHY
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
CN109843324A
(zh)
|
2016-10-06 |
2019-06-04 |
辉瑞公司 |
用于治疗癌症的avelumab用药方案
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
US10322174B2
(en)
|
2016-10-26 |
2019-06-18 |
Cedars-Sinai Medical Center |
Neutralizing anti-TL1A monoclonal antibodies
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
JP2020500508A
(ja)
|
2016-10-28 |
2020-01-16 |
バンヤン・バイオマーカーズ・インコーポレーテッド |
ユビキチンc末端ヒドロラーゼl1(uch−l1)およびグリア線維酸性タンパク質(gfap)に対する抗体および関連する方法
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
CA3039992A1
(en)
|
2016-11-02 |
2018-05-11 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
CN109906030B
(zh)
|
2016-11-04 |
2022-03-18 |
安健基因公司 |
用于产生仅重链抗体的经基因修饰的非人动物和方法
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
EP3548894B1
(en)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
KR102587130B1
(ko)
|
2016-12-07 |
2023-10-11 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
CN117820467A
(zh)
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
CN110072888B
(zh)
|
2016-12-16 |
2023-07-18 |
H.隆德贝克有限公司 |
药剂、用途和方法
|
EP3554542A1
(en)
|
2016-12-19 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
MX2019006954A
(es)
|
2016-12-20 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
|
MX2019007411A
(es)
|
2016-12-21 |
2019-08-29 |
Hoffmann La Roche |
Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
|
MX2019006266A
(es)
|
2016-12-21 |
2019-08-21 |
Hoffmann La Roche |
Glucomanipulacion in vitro de anticuerpos.
|
CN117887794A
(zh)
|
2016-12-21 |
2024-04-16 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
WO2018141768A1
(en)
|
2017-02-02 |
2018-08-09 |
Roche Diagnostics Gmbh |
Immunoassay using at least two pegylated analyte-specific binding agents
|
CR20190387A
(es)
|
2017-02-10 |
2019-09-25 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
TW201837467A
(zh)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
JP7227151B2
(ja)
|
2017-03-22 |
2023-02-21 |
ジェネンテック, インコーポレイテッド |
眼障害の治療のために最適化された抗体組成物
|
AU2018240375C1
(en)
|
2017-03-22 |
2024-02-01 |
Ascendis Pharma A/S |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
WO2018178237A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
US20200048352A1
(en)
|
2017-03-30 |
2020-02-13 |
Merck Patent Gmbh |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
AU2018247765B2
(en)
|
2017-04-03 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
|
WO2018187191A1
(en)
|
2017-04-03 |
2018-10-11 |
Jounce Therapeutics, Inc |
Compositions and methods for the treatment of cancer
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Steap-1に結合する抗体
|
LT3606954T
(lt)
|
2017-04-05 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antikūnai
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
MX2019012793A
(es)
|
2017-04-27 |
2020-02-13 |
Tesaro Inc |
Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
|
CN110831628A
(zh)
|
2017-05-05 |
2020-02-21 |
爱乐科斯公司 |
用于治疗过敏性眼病的方法和组合物
|
EP3401328A1
(en)
|
2017-05-10 |
2018-11-14 |
Bayer Pharma Aktiengesellschaft |
One step antibody humanization by golden gate based germline framework region shuffling
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
SG10202112636SA
(en)
|
2017-05-16 |
2021-12-30 |
Five Prime Therapeutics Inc |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
EP3630829A1
(en)
|
2017-06-02 |
2020-04-08 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
WO2019025299A1
(en)
|
2017-07-31 |
2019-02-07 |
F. Hoffmann-La Roche Ag |
METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
|
RS64419B1
(sr)
|
2017-08-03 |
2023-09-29 |
Alector Llc |
Anti-trem2 antitela i postupci za njihovu upotrebu
|
EP3589658A1
(en)
|
2017-08-03 |
2020-01-08 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
WO2019046338A1
(en)
|
2017-08-28 |
2019-03-07 |
Angiex, Inc. |
ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE
|
EP3684413A1
(en)
|
2017-09-20 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
MA50667A
(fr)
|
2017-09-29 |
2020-08-05 |
Chugai Pharmaceutical Co Ltd |
Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif
|
US11912754B2
(en)
|
2017-10-12 |
2024-02-27 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
US11826414B2
(en)
|
2017-10-23 |
2023-11-28 |
Cz Biohub Sf, Llc |
Measurement of afucosylated IgG Fc glycans and related vaccination methods
|
US11897969B2
(en)
|
2017-10-26 |
2024-02-13 |
The Regents Of The University Of California |
Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
|
MX2020004573A
(es)
|
2017-11-01 |
2020-09-25 |
Hoffmann La Roche |
Terapia de combinacion con agonistas de ox40 dirigidos.
|
EP3704146B1
(en)
|
2017-11-01 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Trifab-contorsbody
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
KR20200103706A
(ko)
|
2017-12-22 |
2020-09-02 |
조운스 테라퓨틱스, 인크. |
Lilrb2에 대한 항체
|
TW201930350A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
US20200339686A1
(en)
|
2018-01-16 |
2020-10-29 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
EP3749361A1
(en)
|
2018-02-08 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
KR20230142806A
(ko)
|
2018-02-09 |
2023-10-11 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
JP7384811B2
(ja)
|
2018-02-16 |
2023-11-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白斑を処置するための方法及び組成物
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202000699A
(zh)
|
2018-02-27 |
2020-01-01 |
瑞士商Ecs前胃泌激素公司 |
將前胃泌激素作為生物標記用於免疫療法的技術
|
MX2020009512A
(es)
|
2018-03-13 |
2020-10-22 |
Hoffmann La Roche |
Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados.
|
KR20200132913A
(ko)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
4-1bb 작용제와 항-cd20 항체의 치료 조합
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
MX2020010028A
(es)
|
2018-03-29 |
2020-10-14 |
Genentech Inc |
Actividad lactogenica modulada en celulas de mamifero.
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
EP3774900A1
(en)
|
2018-04-13 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
CA3098374A1
(en)
|
2018-04-25 |
2019-10-31 |
Prometheus Biosciences, Inc. |
Optimized anti-tl1a antibodies
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
US20210246208A1
(en)
|
2018-05-04 |
2021-08-12 |
Merck Patent Gmbh |
Combined inhibition of pd-1/pd-l1, tgfb and dna-pk for the treatment of cancer
|
CR20200566A
(es)
|
2018-05-25 |
2021-02-19 |
Alector Llc |
Anticuerpos anti-sirpa y metodos de utilización de los mismos
|
BR112020023505A2
(pt)
|
2018-06-01 |
2021-03-30 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Composições e usos das mesmas para tratamento de doença ou condição
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
US20210246204A1
(en)
|
2018-06-08 |
2021-08-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
EP3814377A2
(en)
|
2018-06-29 |
2021-05-05 |
Alector LLC |
Anti-sirp-beta1 antibodies and methods of use thereof
|
KR20230065382A
(ko)
|
2018-07-13 |
2023-05-11 |
알렉터 엘엘씨 |
항-소틸린 항체 및 이들의 사용 방법
|
CN112334479A
(zh)
|
2018-07-13 |
2021-02-05 |
南京传奇生物科技有限公司 |
用于治疗感染性疾病的共受体***
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
CA3106535A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
MX2021001453A
(es)
|
2018-08-08 |
2021-04-12 |
Genentech Inc |
Uso de derivados de triptofano y l-metionina para una formulacion de proteinas.
|
BR112021002037A2
(pt)
|
2018-08-10 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação de antígeno anti-cd137 e uso da mesma
|
WO2020036867A1
(en)
|
2018-08-13 |
2020-02-20 |
Inhibrx, Inc. |
Ox40-binding polypeptides and uses thereof
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
BR112021003018A2
(pt)
|
2018-08-21 |
2021-05-11 |
Albert Einstein College Of Medicine |
anticorpos monoclonais contra tim-3 humana
|
SG11202101875VA
(en)
|
2018-08-28 |
2021-03-30 |
Ambrx Inc |
Anti-cd3 antibody folate bioconjugates and their uses
|
AU2019331018A1
(en)
|
2018-08-31 |
2021-03-11 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3849545A1
(en)
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of neurofibromatosis
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
CN113365697A
(zh)
|
2018-09-25 |
2021-09-07 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
WO2020064971A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
US20230124851A1
(en)
|
2018-10-11 |
2023-04-20 |
Inhibrx, lnc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
CN113166262A
(zh)
|
2018-10-11 |
2021-07-23 |
英伊布里克斯公司 |
Pd-1单结构域抗体及其治疗组合物
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
5t4シングルドメイン抗体およびその治療組成物
|
EP3866785A1
(en)
|
2018-10-15 |
2021-08-25 |
Merck Patent GmbH |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020086858A1
(en)
|
2018-10-24 |
2020-04-30 |
Genentech, Inc. |
Conjugated chemical inducers of degradation and methods of use
|
CA3117856A1
(en)
|
2018-10-31 |
2020-05-07 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
JP7499760B2
(ja)
|
2018-11-02 |
2024-06-14 |
アネクソン,インコーポレーテッド |
脳損傷を治療するための組成物及び方法
|
JP2022506156A
(ja)
|
2018-11-05 |
2022-01-17 |
ジェネンテック, インコーポレイテッド |
原核宿主細胞における2鎖タンパク質の産生方法
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
AU2019392711A1
(en)
|
2018-12-05 |
2021-05-20 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
改変抗体fcおよび使用方法
|
US20230071889A1
(en)
|
2018-12-21 |
2023-03-09 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
KR20210107058A
(ko)
|
2018-12-21 |
2021-08-31 |
오제 이뮈노테라프틱스 |
인간 pd-1에 대항하는 이작용성 분자
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
WO2020132231A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
CN113286822A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的超激动性cd28抗原结合分子
|
UA128001C2
(uk)
|
2018-12-21 |
2024-03-06 |
Ф. Хоффманн-Ля Рош Аг |
Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
|
JP2022514698A
(ja)
|
2018-12-21 |
2022-02-14 |
オーエスイー・イミュノセラピューティクス |
二機能性抗pd-1/sirpa分子
|
KR20210107721A
(ko)
|
2018-12-21 |
2021-09-01 |
23앤드미 인코포레이티드 |
항-il-36 항체 및 이의 사용 방법
|
MX2021007769A
(es)
|
2018-12-26 |
2021-09-23 |
Xilio Dev Inc |
Proteínas de unión anti-ctla4 enmascaradas activables.
|
CN113272327A
(zh)
|
2018-12-30 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
抗兔cd19抗体及其使用方法
|
WO2020146221A1
(en)
|
2019-01-07 |
2020-07-16 |
Inhibrx, Inc. |
Polypeptides comprising modified il-2 polypeptides and uses thereof
|
CA3124837A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
US20220128561A1
(en)
|
2019-01-17 |
2022-04-28 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
|
MX2021008621A
(es)
|
2019-01-22 |
2021-08-19 |
Genentech Inc |
Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
CN113543799A
(zh)
|
2019-03-01 |
2021-10-22 |
艾洛基治疗公司 |
靶向dll3的嵌合抗原受体和结合剂
|
KR20210138588A
(ko)
|
2019-03-08 |
2021-11-19 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
MA55296A
(fr)
|
2019-03-14 |
2022-03-23 |
Hoffmann La Roche |
Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
|
KR20210141948A
(ko)
|
2019-03-19 |
2021-11-23 |
앨버트 아인슈타인 컬리지 오브 메디신 |
단순 헤르페스 바이러스 감염의 예방 및 치료를 위한 모노클로날 항체
|
AU2020240339A1
(en)
|
2019-03-21 |
2021-08-26 |
Allogene Therapeutics, Inc. |
Methods for enhancing TCRαβ+ cell depletion efficiency
|
EP3946330A1
(en)
|
2019-03-29 |
2022-02-09 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
EP3952996A1
(en)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising lipocalin muteins
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
CA3132509A1
(en)
|
2019-04-26 |
2020-10-29 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car t cells
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
US11560428B2
(en)
|
2019-05-04 |
2023-01-24 |
Inhibrx, Inc. |
CD33-binding polypeptides and uses thereof
|
AU2020269268A1
(en)
|
2019-05-04 |
2021-11-11 |
Inhibrx Biosciences, Inc. |
CD123-binding polypeptides and uses thereof
|
JP2022531306A
(ja)
|
2019-05-04 |
2022-07-06 |
インヒブルクス インコーポレイテッド |
CLEC12a結合性ポリペプチド及びその使用
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
JP2022536839A
(ja)
|
2019-06-11 |
2022-08-19 |
アレクトル エルエルシー |
治療に使用するための抗ソルチリン抗体
|
TW202115124A
(zh)
|
2019-06-26 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
結合至cea之新穎抗原結合分子
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
BR112021026492A2
(pt)
|
2019-06-28 |
2022-02-08 |
Genentech Inc |
Formulações líquidas, formulação liofilizada, artigos de fabricação e método para preparar uma formulação líquida
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
CR20220078A
(es)
|
2019-07-31 |
2022-06-24 |
Alector Llc |
Anticuerpos anti-ms4a4a y métodos de uso de los mismos
|
EP4003526A2
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
CA3148740A1
(en)
|
2019-08-06 |
2021-02-11 |
Aprinoia Therapeutics Limited |
Antibodies that bind to pathological tau species and uses thereof
|
BR112022002406A2
(pt)
|
2019-08-12 |
2022-07-19 |
Purinomia Biotech Inc |
Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39
|
KR20220088847A
(ko)
|
2019-09-04 |
2022-06-28 |
주식회사 와이바이오로직스 |
항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
AU2020349509A1
(en)
|
2019-09-18 |
2022-03-31 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
TW202126699A
(zh)
|
2019-09-20 |
2021-07-16 |
美商建南德克公司 |
用於抗類胰蛋白酶抗體之投藥
|
WO2021059075A1
(en)
|
2019-09-27 |
2021-04-01 |
Janssen Biotech, Inc. |
Anti-ceacam antibodies and uses thereof
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
EP4045090A1
(en)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
AU2020371725A1
(en)
|
2019-10-24 |
2022-05-26 |
Cedars-Sinai Medical Center |
Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
|
WO2021084124A1
(en)
|
2019-11-01 |
2021-05-06 |
Ares Trading S.A. |
COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
|
IL292758A
(en)
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Combined inhibition of pd-1, tgf-beta and tigit for cancer therapy
|
BR112022004998A2
(pt)
|
2019-11-05 |
2022-06-14 |
Merck Patent Gmbh |
Anticorpos anti-tigit e usos dos mesmos
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
AU2020384917A1
(en)
|
2019-11-15 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in aqueous protein solutions
|
CA3158565A1
(en)
|
2019-12-05 |
2021-06-10 |
Tina SCHWABE |
Methods of use of anti-trem2 antibodies
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
BR112022010627A2
(pt)
|
2019-12-06 |
2022-08-16 |
Juno Therapeutics Inc |
Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
|
US20230039268A1
(en)
|
2019-12-09 |
2023-02-09 |
Genentech, Inc. |
Anti-pd-l1 antibody formulations
|
US20230035072A1
(en)
|
2019-12-12 |
2023-02-02 |
Alector Llc |
Methods of use of anti-cd33 antibodies
|
AU2020401319A1
(en)
|
2019-12-13 |
2022-06-30 |
Alector Llc |
Anti-MerTK antibodies and methods of use thereof
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
KR20220100963A
(ko)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Hla-a2/mage-a4에 결합하는 항체
|
JP2023509390A
(ja)
|
2019-12-23 |
2023-03-08 |
ジェネンテック, インコーポレイテッド |
アポリポタンパク質l1特異的抗体及びその使用方法
|
BR112022011723A2
(pt)
|
2019-12-27 |
2022-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-ctla-4 e uso do mesmo
|
CA3162009A1
(en)
|
2020-01-09 |
2021-07-15 |
F. Hoffmann-La Roche Ag |
New 4-1bbl trimer-containing antigen binding molecules
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
EP4090770A1
(en)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202142230A
(zh)
|
2020-01-27 |
2021-11-16 |
美商建南德克公司 |
用於以抗tigit拮抗體抗體治療癌症之方法
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
AU2021218927A1
(en)
|
2020-02-10 |
2022-09-22 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
EP4105237A4
(en)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co Ltd |
ANTI-CLDN18.2 ANTIBODIES AND ITS USE
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
EP4103285A2
(en)
|
2020-02-14 |
2022-12-21 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
JP2023515478A
(ja)
|
2020-02-24 |
2023-04-13 |
アレクトル エルエルシー |
抗trem2抗体の使用方法
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
KR20220148209A
(ko)
|
2020-02-28 |
2022-11-04 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물 및 그 용도
|
JP2023516941A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト、多重特異性抗体及びその使用
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
KR20220152262A
(ko)
|
2020-03-13 |
2022-11-15 |
제넨테크, 인크. |
항-인터루킨-33 항체 및 이의 용도
|
AU2021236660A1
(en)
|
2020-03-19 |
2022-08-18 |
Genentech, Inc. |
Isoform-selective anti-TGF-beta antibodies and methods of use
|
BR112022018847A2
(pt)
|
2020-03-24 |
2022-11-22 |
Genentech Inc |
Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
CA3172451A1
(en)
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021207348A1
(en)
|
2020-04-07 |
2021-10-14 |
Albert Einstein College Of Medicine |
Method of treating and preventing ocular disease with hsv-2 delta gd
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
BR112022020629A2
(pt)
|
2020-04-15 |
2022-11-29 |
Hoffmann La Roche |
Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
|
JP2023522930A
(ja)
|
2020-04-24 |
2023-06-01 |
ジェネンテック, インコーポレイテッド |
抗CD79b免疫抱合体の使用方法
|
CA3172880A1
(en)
|
2020-04-27 |
2021-11-04 |
Sotirios Tsimikas |
Isoform-independent antibodies to lipoprotein(a)
|
KR20230002261A
(ko)
|
2020-04-28 |
2023-01-05 |
더 락커펠러 유니버시티 |
항-sars-cov-2 중화 항체 및 이의 사용 방법
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁(苏州)生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
WO2021228917A1
(en)
|
2020-05-15 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in parenteral protein solutions
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
AU2021281417A1
(en)
|
2020-05-29 |
2022-12-08 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
MX2022015376A
(es)
|
2020-06-02 |
2023-04-14 |
Dynamicure Biotechnology Llc |
Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
JP2023527918A
(ja)
|
2020-06-08 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗hbv抗体及び使用方法
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
BR112022025809A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpos, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo, uso do anticorpo, método para tratar uma doença e invenção
|
TW202219065A
(zh)
|
2020-06-19 |
2022-05-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫活化 Fc 域結合分子
|
KR20230025665A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Cd3에 결합하는 항체
|
MX2022015890A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos biespecificos para linfocitos t activados por proteasa.
|
JP2023538716A
(ja)
|
2020-06-19 |
2023-09-11 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3及びcd19に結合する抗体
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗il-36抗体およびその使用方法
|
WO2021259890A1
(en)
|
2020-06-23 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Agonistic cd28 antigen binding molecules targeting her2
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
CN115916830A
(zh)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
抗cd3/抗cd28双特异性抗原结合分子
|
KR20230035076A
(ko)
|
2020-07-02 |
2023-03-10 |
인히브릭스, 인크. |
변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도
|
WO2022008468A1
(en)
|
2020-07-07 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
PE20231300A1
(es)
|
2020-07-17 |
2023-08-24 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
JP2023535409A
(ja)
|
2020-07-21 |
2023-08-17 |
ジェネンテック, インコーポレイテッド |
Brm分解の抗体コンジュゲート化化学的誘導物質及びbrm分解の方法
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2022023379A1
(en)
|
2020-07-28 |
2022-02-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for preventing and treating a cancer
|
WO2022026763A1
(en)
|
2020-07-29 |
2022-02-03 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
CA3192323A1
(en)
|
2020-09-14 |
2022-03-17 |
Julie MACOIN |
Antibodies that bind to il1rap and uses thereof
|
AU2021343834A1
(en)
|
2020-09-15 |
2023-04-13 |
Bayer Aktiengesellschaft |
Novel anti-A2AP antibodies and uses thereof
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
CA3190782A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AU2021370991A1
(en)
|
2020-11-02 |
2023-06-22 |
Ares Trading S.A. |
Combination treatment of cancer
|
CA3196557A1
(en)
|
2020-11-02 |
2022-05-05 |
Ada SALA-HOJMAN |
Combination treatment of cancer
|
US20220162329A1
(en)
|
2020-11-04 |
2022-05-26 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
JP2023548064A
(ja)
|
2020-11-04 |
2023-11-15 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体及び抗cd79b抗体薬物コンジュゲートによる処置のための投与
|
WO2022098628A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
KR20230109674A
(ko)
|
2020-11-16 |
2023-07-20 |
에프. 호프만-라 로슈 아게 |
Fab 고 만노스 당형
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
JP2023551563A
(ja)
|
2020-12-04 |
2023-12-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
pH依存性変異体インターロイキン-2ポリペプチド
|
CA3200770A1
(en)
|
2020-12-14 |
2022-06-23 |
Lillian SEU |
Methods and reagents for characterizing car t cells for therapies
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
TW202245811A
(zh)
|
2021-02-03 |
2022-12-01 |
美商異基因治療有限公司 |
用於car t細胞藥物產品的調配物與製程
|
AU2022223977A1
(en)
|
2021-02-19 |
2023-08-17 |
Inhibrx Biosciences, Inc. |
Formulations of dr5 binding polypeptides
|
EP4298123A2
(en)
|
2021-02-26 |
2024-01-03 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
US20240158503A1
(en)
|
2021-03-03 |
2024-05-16 |
Pierre Fabre Medicament |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
CN117440832A
(zh)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
包括抗bcma抗体的抗体-药物缀合物
|
US20240141048A1
(en)
|
2021-03-05 |
2024-05-02 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
CN117083084A
(zh)
|
2021-03-09 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
Pd-1靶向il-2变体免疫缀合物和fap/4-1bb结合分子的组合疗法
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
JP2024518013A
(ja)
|
2021-03-10 |
2024-04-24 |
イミュノウェイク インコーポレイテッド |
免疫調節分子及びその使用
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
US20240165094A1
(en)
|
2021-03-17 |
2024-05-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
CN116981696A
(zh)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
WO2022204070A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
CN117616041A
(zh)
|
2021-03-25 |
2024-02-27 |
当康生物技术有限责任公司 |
抗-igfbp7构建体及其用途
|
CA3215274A1
(en)
|
2021-03-30 |
2022-10-06 |
Bayer Aktiengesellschaft |
Anti-sema3a antibodies and uses thereof
|
JP2024512709A
(ja)
|
2021-03-30 |
2024-03-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ポリペプチド
|
WO2022216898A1
(en)
|
2021-04-09 |
2022-10-13 |
Genentech, Inc. |
Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
KR20230173164A
(ko)
|
2021-04-19 |
2023-12-26 |
제넨테크, 인크. |
변형된 포유류 세포
|
US20240158861A1
(en)
|
2021-04-23 |
2024-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
JP2024517535A
(ja)
|
2021-04-30 |
2024-04-23 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体と抗cd79b抗体薬物コンジュゲートを用いた併用治療の投与
|
TW202309088A
(zh)
|
2021-04-30 |
2023-03-01 |
法商皮爾法伯製藥公司 |
新的穩定抗vista抗體
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
CN117222435A
(zh)
|
2021-05-03 |
2023-12-12 |
默克专利有限公司 |
HER2靶向Fc抗原结合片段-药物缀合物
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
KR20240007928A
(ko)
|
2021-05-14 |
2024-01-17 |
제넨테크, 인크. |
Trem2의 효능제
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
CA3221411A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
JP2024520764A
(ja)
|
2021-06-07 |
2024-05-24 |
アレス トレーディング ソシエテ アノニム |
癌の組み合わせ処置
|
EP4351582A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
IL308633A
(en)
|
2021-06-25 |
2024-01-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-CTLA-4 antibodies
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
CA3225636A1
(en)
|
2021-07-02 |
2023-01-05 |
Merck Patent Gmbh |
Anti-protac antibodies and complexes
|
WO2023288241A1
(en)
|
2021-07-14 |
2023-01-19 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
EP4373854A1
(en)
|
2021-07-20 |
2024-05-29 |
Inhibrx, Inc. |
Cd8-binding polypeptides and uses thereof
|
TW202309102A
(zh)
|
2021-07-20 |
2023-03-01 |
美商英伊布里克斯公司 |
靶向cd8之經修飾il-2多肽及其用途
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CA3227537A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
KR20240038768A
(ko)
|
2021-07-30 |
2024-03-25 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키메라 단백질 및 면역치료 방법
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
CN117858905A
(zh)
|
2021-08-19 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
多价抗变体fc区抗体及使用方法
|
KR20240049296A
(ko)
|
2021-08-27 |
2024-04-16 |
제넨테크, 인크. |
타우 병증을 치료하는 방법
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
CN118043352A
(zh)
|
2021-09-02 |
2024-05-14 |
德国癌症研究中心公共法律基金会 |
副作用减少的抗cecam6抗体
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
JPWO2023058723A1
(pt)
|
2021-10-08 |
2023-04-13 |
|
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AU2022389969A1
(en)
|
2021-11-16 |
2024-05-02 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
CA3240565A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies and methods of use
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
TW202334193A
(zh)
|
2022-01-05 |
2023-09-01 |
美商英伊布里克斯公司 |
靶向γδ T細胞之經修飾IL-2多肽及其用途
|
WO2023133394A1
(en)
|
2022-01-05 |
2023-07-13 |
Inhibrx, Inc. |
Gamma delta t-cell-binding polypeptides and uses thereof
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023170247A1
(en)
|
2022-03-11 |
2023-09-14 |
Mablink Bioscience |
Antibody-drug conjugates and their uses
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023186760A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Improved folr1 protease-activatable t cell bispecific antibodies
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196943A1
(en)
|
2022-04-08 |
2023-10-12 |
Inhibrx, Inc. |
Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
|
TW202408562A
(zh)
|
2022-04-13 |
2024-03-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
US20230407252A1
(en)
|
2022-04-28 |
2023-12-21 |
Allogene Therapeutics, Inc. |
Methods for donor cell analysis
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023213814A1
(en)
|
2022-05-02 |
2023-11-09 |
Pierre Fabre Medicament |
New formulation of anti vista antibody
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
TW202406933A
(zh)
|
2022-05-05 |
2024-02-16 |
美商英伊布里克斯公司 |
白蛋白結合多肽及其用途
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023230432A1
(en)
|
2022-05-23 |
2023-11-30 |
Inhibrx, Inc. |
Dr5 agonist and iap antagonist combination therapy
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023240218A1
(en)
|
2022-06-09 |
2023-12-14 |
Allogene Therapeutics Inc. |
Methods for detecting genomic abnormalities in cells
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2023240216A1
(en)
|
2022-06-11 |
2023-12-14 |
Inhibrx, Inc. |
Fcrn-binding polypeptides and uses thereof
|
WO2023245008A1
(en)
|
2022-06-13 |
2023-12-21 |
Genentech, Inc. |
Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
US20240132622A1
(en)
|
2022-07-22 |
2024-04-25 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
US20240085403A1
(en)
|
2022-08-16 |
2024-03-14 |
Allogene Therapeutics, Inc. |
Method for inhibiting adventitious viral infection
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024097741A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|